Exhibit 99.1

 

 

 

Contact:

 

 

Investors:

 

Media:

Traci McCarty

 

Debra Charlesworth

BioMarin Pharmaceutical Inc.

 

BioMarin Pharmaceutical Inc.

(415) 455-7558

 

(415) 455-7451

 

 

 

 

 

BioMarin Announces Third Quarter 2018 Results

 

- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion

- 124 Commercial Patients Receiving Treatment with Palynziq in First Full Quarter since U.S. Approval

- Vosoritide 42-Month Data; PKU Gene Therapy Preclinical Data and Research Deep Dive

at R&D Day on November 7 in New York City

 

 

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2018

 

 

2017

 

 

% Change

 

 

2018

 

 

2017

 

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$

391.7

 

 

$

334.1

 

 

 

17

%

 

$

1,138.0

 

 

$

955.3

 

 

 

19

%

Vimizim Net Product Revenues

 

 

123.3

 

 

 

90.3

 

 

 

37

%

 

 

368.0

 

 

 

299.3

 

 

 

23

%

Kuvan Net Product Revenues

 

 

113.3

 

 

 

105.8

 

 

 

7

%

 

 

321.4

 

 

 

300.1

 

 

 

7

%

Naglazyme Net Product Revenues

 

 

103.1

 

 

 

72.1

 

 

 

43

%

 

 

269.2

 

 

 

238.4

 

 

 

13

%

Aldurazyme Net Product Revenues

 

 

27.6

 

 

 

22.4

 

 

 

23

%

 

 

117.7

 

 

 

61.7

 

 

 

91

%

Brineura Net Product Revenues

 

 

9.9

 

 

 

3.1

 

 

 

219

%

 

 

27.7

 

 

 

3.4

 

 

 

715

%

Palynziq Net Product Revenues

 

 

4.1

 

 

 

 

 

n/a

 

 

 

4.1

 

 

 

 

 

n/a

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP Net Loss

 

$

(12.6

)

 

$

(12.5

)

 

 

 

 

 

$

(73.6

)

 

$

(65.7

)

 

 

 

 

GAAP Net Loss per Share - Basic and Diluted

 

$

(0.07

)

 

$

(0.07

)

 

 

 

 

 

$

(0.42

)

 

$

(0.38

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Income (1)

 

$

60.7

 

 

$

7.8

 

 

 

 

 

 

$

101.8

 

 

$

68.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

 

December 31,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and investments

 

$

1,648.3

 

 

$

1,781.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

Non-GAAP Income is defined by the Company as reported GAAP Net Income (Loss), excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items. Refer to Non-GAAP Information beginning on page 9 of this press release for a complete discussion of the Company’s Non-GAAP financial information and reconciliations to the comparable information reported under Generally Accepted Accounting Principles in the United States (US GAAP).

 

1

 


The following information was filed by Biomarin Pharmaceutical Inc (BMRN) on Thursday, October 25, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Biomarin Pharmaceutical Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biomarin Pharmaceutical Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account